About Augmenix
Augmenix is a Healthcare company based in Waltham (United States) founded in 2008, and was acquired by Boston Scientific in September 2018. It operates as a hydrogel spacers are provided for prostate cancer radiation therapy. Augmenix has raised $46.6 million across 7 funding rounds from investors including Boston Scientific, Varian and Pinnacle Ventures. The company has 153 employees. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its legal entity is AUGMENIX, INC. Its competitors include AmacaThera, Regentis Biomaterials, LifeSprout, Biosyntech and ECM Therapeutics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Provider of a hydrogel spacer for prostate cancer radiation therapy. This hydrogel is injected to create space between the rectum and prostate, reducing radiation exposure to the rectum during treatment. The procedure aims to minimize urinary, sexual, and bowel side effects associated with radiation therapy. The hydrogel is made of polyethylene glycol (PEG) and is intended for temporary use during radiotherapy. Potential complications, though rare, include injection site pain, inflammation, and other issues. Patients should discuss risks and benefits with their physician before treatment.
- Headquarters Waltham, United States
- Employees 153
- SectorsHealthcare
- Website augmenix.com
- Social LinkedIn
- Acquired by Boston Scientific (Sep 2018)
- Legal Name Augmenix, Inc
- Total Equity Funding$46.6M (USD)
in 7 rounds
- Latest Funding Round$6M (USD), Series E
Jul 2016
- InvestorsBoston Scientific
& 7 more
- Employee Count153
- Acquired byBoston Scientific
(Sep 2018)
Funding Insights of Augmenix
Augmenix has successfully raised a total of $46.6M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $6 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.6M
- Total Rounds 7
- Last Round Series E — $6M
- First Round $1M
(Feb 2008)
- Investors Count 7
All 7 funding rounds of Augmenix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $6M | Series E | – | – | – |
| Jul 2014 | $10.8M | Series D | – | – | |
| May 2011 | $15M | Series C | – | – | |
| Nov 2010 | $3M | Series B | – | – | – |
| Oct 2009 | $6.1M | Series B | – | – | |
| Jul 2009 | $4.7M | Series A | – | – | – |
| Feb 2008 | $1M | Seed | – | Incept, Versant Ventures | – |
8 investors in total: 8 institutional.
Investors in Augmenix
Augmenix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Varian and Pinnacle Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Late stage tech-focused VC firm funding companies in the US | – | excelestarventures.com | Andover, United States | |
- | – | catalysthealthventures.com | - | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Strategic investments in healthcare technologies and data innovations. | – | ascensionventures.org | - | |
Venture debt and equity financing are provided across US sectors. | 2002 | pinnacleventures.com | Palo Alto, United States | |
Medical innovations are accelerated from concept to commercialization by Incept. | – | inceptllc.com | Bedford, USA | |
Varian is focused on developing cancer treatment technologies. | 1948 | varian.com | Palo Alto, United States | |
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Augmenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Augmenix
4 dated milestones of Augmenix across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Augmenix is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series E, of $6.0M.
- Exit Acquired by Boston Scientific.
Competitors of Augmenix
Augmenix has 9 listed competitors in our database, 8 of them funded. They include AmacaThera, Regentis Biomaterials, LifeSprout, Biosyntech and ECM Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amacathera.ca | 2015 | Toronto, Canada | $14.22M | – | Injectable hydrogel platform developed for therapeutic medical applications. | |
| regentis.co.il | 2004 | Or Akiva, Israel | $25M | – | Regentis Biomaterials is focused on tissue repair hydrogel technology. | |
| lifesproutbio.com | 2015 | Baltimore, United States | $44.7M | 12 | Synthetic soft tissue substitutes for cosmetics and reconstructive surgery | |
| biosyntech.com | 1994 | Laval, Canada | $1.4M | – | Biotherapeutic thermogels are developed for tissue repair applications. | |
| ecmtherapeutics.com | 2018 | Warrendale, United States | $26.1M | – | Diagnostic and therapeutic products from extracellular matrix are developed. | |
| carbylan.com | 2004 | Palo Alto, United States | $42.9M | 7 | Hyaluronic acid polymers are developed into therapeutics for pain management. | |
| lonestarheartinc.com | 2010 | Laguna Hills, United States | $45.18M | 2 | Develops cardiac therapies for patients with chronic heart failure. | |
| orthotrophix.com | 2011 | Oakland, United States | – | – | Develops and commercializes therapies for hard tissue diseases like osteoarthritis. | |
| glycosan.com | 2006 | Alameda, United States | $950,000 | – | Biocompatible hydrogels mimicking extracellular matrix are developed for tissue engineering. |
Detailed competitors of Augmenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Organ-on-Chip & Regenerative Solutions
10 companies that operate in the same segment as Augmenix (Organ-on-Chip & Regenerative Solutions), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Products for regenerative and respiratory medicine are developed and distributed. | 1992 | Cambridge, Cambridgeshire, United Kingdom | – | USD 71.61 M | 260 | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Synthetic adhesives for bone and dental repair are developed. | 2014 | Lowell, Massachusetts, United States | USD 24.42 M | – | – | |
Injectable synthetic bone substitutes are developed for fracture treatment. | 2000 | Lund, Sweden | USD 101.08 M | USD 127.04 M | 139 | |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | 2019 | Boston, Massachusetts, United States | USD 205 M | – | 52 | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Reconstructive and regenerative solutions for bone conditions are developed. | 1980 | Lewisville, Texas, United States | – | USD 822.31 M | 1,620 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Augmenix
Complete news archive for Augmenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Augmenix
Augmenix was founded in 2008.
Augmenix is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Augmenix is a funded company, having raised a total of $46.6M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Feb 2008.
Augmenix has 153 employees.
Provider of a hydrogel spacer for prostate cancer radiation therapy. This hydrogel is injected to create space between the rectum and prostate, reducing radiation exposure to the rectum during treatment. The procedure aims to minimize urinary, sexual, and bowel side effects associated with radiation therapy. The hydrogel is made of polyethylene glycol (PEG) and is intended for temporary use during radiotherapy. Potential complications, though rare, include injection site pain, inflammation, and other issues. Patients should discuss risks and benefits with their physician before treatment.
Augmenix's top competitors include AmacaThera, LifeSprout and Regentis Biomaterials.
Augmenix has 8 investors. Key investors include Boston Scientific, Varian, Pinnacle Ventures, Excelestar Ventures, and Catalyst Health Ventures.
Augmenix operates through Augmenix, Inc.
Yes. Augmenix was acquired by Boston Scientific in September 2018.